Severe Acute Respiratory-Syndrome Treatment Market Report 2026

Severe Acute Respiratory-Syndrome Treatment Market Overview

• Severe Acute Respiratory-Syndrome Treatment market size has reached to $3.94 billion in 2025 • Expected to grow to $8.33 billion in 2030 at a compound annual growth rate (CAGR) of 16.4% • Growth Driver: Surging Respiratory Disease Cases Fuel Growth In The Severe Acute Respiratory Syndrome Treatment Market • Market Trend: Emergence Of Oral Antiviral Therapies Revolutionizing Severe Acute Respiratory Syndrome Treatment • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Severe Acute Respiratory-Syndrome Treatment Market?

Severe acute respiratory syndrome (SARS) refers to a serious form of pneumonia caused by an airborne virus that can spread through tiny droplets of saliva. It is previously unrecognized virus from the Coronaviridae family, the SARS-associated COVID-19 (SARS-CoV). Severe acute respiratory syndrome (SARS) treatment involves the medical interventions and supportive measures implemented to manage the symptoms and complications of the viral respiratory illness. The main classes of drugs used in severe acute respiratory-syndrome treatment are antibiotics, antivirals, corticosteroids, monoclonal antibodies and others. Antibiotics refer to a class of medications used to treat bacterial infections. They work by either killing bacteria or inhibiting their growth, depending on the specific type of antibiotic. They are administered through oral and intravenous routes for the treatment of severe acute respiratory syndrome COVID-19 (SARS-CoV) and severe acute respiratory syndrome COVID-19 2 (SARS-CoV 2). These are distributed through hospital pharmacies, retail pharmacies and others.

What Is The Severe Acute Respiratory-Syndrome Treatment Market Growth Forecast?

The severe acute respiratory-syndrome treatment market size is expected to see rapid growth in the next few years. It will grow to $8.33 billion in 2030 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to AI-assisted treatment protocols, development of novel antivirals, telemedicine-enabled critical care, global pandemic preparedness programs, investment in rapid diagnostics and treatment monitoring. Major trends in the forecast period include antiviral drug therapies, monoclonal antibodies, convalescent plasma therapy, tele-ICU integration, AI-based treatment monitoring.

Global Severe Acute Respiratory-Syndrome Treatment Market Segmentation

1) By Drug Class: Antibiotics, Antiviral, Corticosteroids, Monoclonal Antibodies, Other Drug Classes 2) By Route Of Administration: Oral, Intravenous 3) By Indication: Severe Acute Respiratory Syndrome COVID-19 (SARS-CoV), Severe Acute Respiratory Syndrome COVID-19 2 (SARS‑CoV‑2) 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels Subsegments: 1) By Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics 2) By Antiviral: Nucleoside Analogs, Protease Inhibitors 3) By Corticosteroids: Systemic Corticosteroids, Inhaled Corticosteroids 4) By Monoclonal Antibodies: Neutralizing Antibodies, Non-Neutralizing Antibodies 5) By Other Drug Classes: Immunomodulators, Supportive Medications

What Is The Driver Of The Severe Acute Respiratory-Syndrome Treatment Market?

The growing incidence of respiratory diseases is expected to propel the growth of the severe acute respiratory syndrome treatment market going forward. Respiratory diseases refer to a group of medical conditions that affect the respiratory system responsible for breathing and the exchange of gases between the body and the external environment. Severe acute respiratory syndrome treatment is used in respiratory diseases to alleviate symptoms, prevent respiratory failure, reduce inflammation and maintain oxygen levels. For instance, in December 2023, according to the National Library of Medicine, a US-based medical library, the global number of chronic obstructive pulmonary disease (COPD) cases among those 25 and older is projected to rise by 23% by 2050, reaching nearly 600 million. Therefore, the growing incidence of respiratory diseases is driving the growth of the severe acute respiratory syndrome treatment market.

Key Players In The Global Severe Acute Respiratory-Syndrome Treatment Market

Major companies operating in the severe acute respiratory-syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline plc, AstraZeneca plc, Sanofi SA, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Johnson And Johnson Private Limited, Moderna Inc., Regeneron Pharmaceuticals Inc., Hetero Labs Ltd., Alexion Pharmaceuticals Inc., Cadila Healthcare Ltd., Genentech Inc., Cipla Ltd., Biogen Inc., Vir Biotechnology Inc., Swedish Orphan Biovitrum AB, Dynavax Technologies Corporation, Panacea Biotec Limited, CureVac N.V., Inovio Pharmaceuticals Inc., Chimerix Inc.

Global Severe Acute Respiratory-Syndrome Treatment Market Trends and Insights

Major companies operating in the severe acute respiratory syndrome treatment market are focusing on technological advancements, such as oral antiviral therapies designed to inhibit viral replication and reduce disease severity, to meet the rising demand driven by recurrent coronavirus outbreaks and the urgent need for effective outpatient treatments. For instance, in September 2025, Shionogi & Co., Ltd., a Japan-based pharmaceutical company, launched Ensitrelvir, the first oral antiviral therapy approved for the prevention and treatment of SARS-CoV infections. Ensitrelvir works by selectively inhibiting the 3C-like protease, an enzyme essential for viral replication, offering a targeted mechanism that reduces viral load and mitigates symptoms more effectively than traditional supportive care. The medication is designed for easy oral administration, enabling wider community access and early intervention to prevent severe disease progression. This innovation represents a critical advancement in managing SARS amid evolving viral strains and healthcare demands.

What Are Latest Mergers And Acquisitions In The Severe Acute Respiratory-Syndrome Treatment Market?

In February 2023, Vir Biotechnology, a US-based immunology company developing therapies to treat and prevent serious infectious diseases, partnered with GSK plc to continue advancing next-generation COVID-19 and coronavirus-based solutions independently (or with new partners), while maintaining joint collaboration with GSK on sotrovimab and other respiratory-disease programs. GSK plc is a UK-based provider of vaccines, antibody platforms, and respiratory-virus R&D.

Regional Outlook

North America was the largest region in the severe acute respiratory syndrome treatment market in 2025. Western Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Severe Acute Respiratory-Syndrome Treatment Market?

The severe acute respiratory syndrome treatment market consists of revenues earned by entities by providing services such as respiratory therapy, oxygen therapy, ventilation, intensive care, isolation and infection control, fluid and electrolyte management and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The severe acute respiratory syndrome treatment market also includes sales of azithromycin, immunomodulators, vaccines, ribavirin, ritonavir, remdesivir, methylprednisolone, prednisolone, dexamethasone and interferon. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Severe Acute Respiratory-Syndrome Treatment Market Report 2026?

The severe acute respiratory-syndrome treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the severe acute respiratory-syndrome treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.